

Market Analysis – Infectious Disease 2020

Mariana Nascimento

Federal Institute of Education, Science and Technology Sul-Rio-Grandense, RS, Brazil, E-mail:
mariananascimento@gmail.com

Allied Academies has a huge pleasure in organizing [Infectious Disease 2020 congress](#). In this many technological development for curing the diseases will be studied. Several research works are performed in treating, controlling and preventing numerous diseases and this platform will be the stage for many professionals, scientist, scholars and industrialist for their new ideal innovations.

The worldwide [Infectious disease](#) diagnostics market was estimated at USD 13.93 Billion in 2016 and predicted to achieve USD 19.35 Billion in 2022, at a CAGR of 5.6%. The base year is taken into account for the analysis is 2016, and the prediction for the market size is offered for the interval between 2018 and 2022. Expansion in this market is principally constrained by the growing global occurrence of Infectious diseases, shift in focus from integrated research laboratory to decentralized point-of-care testing, and development in funding for investigation on Infectious disease diagnostics.

Increasing prevalence of target diseases, increasing health consciousness among people, and elevated demand for self-care medical devices are anticipated to promote the expansion of the market through the forecast period. Moreover, establishment of novel products with improved sensitivity, speed, and user-friendliness is estimated to augment the adoption of Invitro Diagnostic tests for infectious diseases over the coming years. Technological improvements such as convenient Real Time Polymerase Chain Reaction (qPCR) and expanding market penetration of technologies such as self-testing devices are key drivers in this therapeutic area. However, presence of uncertain regulatory framework and high price of Invitro Diagnostic tests are inhibiting the progress of the market.

Expanding worldwide prevalence of Infectious diseases

The overall existence of infectious diseases such as influenza, HPV, hepatitis, HIV, and tuberculosis is remarkably high in spite of substantial advances in public health practices and medicine. Many of the presently available analytical practices are slow, include complex procedures, and deficient in specific detection of causative microbial agents. Due to this, patients are obtaining empiric, wide-spectrum antimicrobial therapy as an alternative of appropriate therapies. This caused the improvement of super-resistant microbes.

Growing awareness about personalized medicine

Expanding awareness in patients about the enhancements of personalized medicine is one of the vital considerations resulting in the enhanced use of molecular diagnostics and genomics & proteomics knowledges in infectious disease testing. Diagnostic tests can be applied to evaluate the effectiveness of certain therapeutic agents in specific patients. With the assistance of

*2nd International Conference on Pathology and Infectious Diseases
July 27-28, 2020 / Singapore*

diagnostic tests, patients who undergo disproportionately severe harmful effects from a given medication or dosage can be detected. Moreover, analytic tests help in deciding the optimal dosages for drugs whose therapeutic effects are known to vary widely among different patient groups. The extent or progression of a disease and preventive actions can be detected in patients through diagnostic assessments. With the rising demand for personalized medicine, the requirement for such diagnostic tests is projected to increase worldwide.

One of the most broadly used customized treatment regimens contains therapeutic drug monitoring tests to choose drugs for resistant HIV strains. The increasing availability of genetic and molecular diagnostic tests performs a crucial role in empowering the initial discovery of infections and offering more personalized medications; this can potentially result in substantial savings in medication costs

Research Methodology

The research report validates the size of the global [Infectious disease](#) diagnostics market and assess the size of several other related submarkets. Most Important players in the market were recognized through secondary study and their market presence was analysed through primary and secondary research.

Applications Perceptions:

In-Vitro Diagnostics (IVD) devices are employed in testing and diagnosis of numerous infectious diseases, such as HIV, Methicillin-resistant Staphylococcus aureus (MRSA), streptococcal infections, influenza, and hepatitis. HIV diagnostic assessments carried the largest share in the IVD infectious diseases market in 2018. The part is primarily driven by high disease burden, low consumer awareness, and unmet clinical needs in developing countries.

Key players are revising range of test menus for their qPCR instruments by undertaking R&D initiatives for advancement of kits to curb evolving diseases or by arriving into agreements with other kit manufacturing companies.

Scope of the Report

The research report classifies the global market into the following sectors and subsectors:

Market, by Product & Service

- Assays, Kits, & Reagents
- Instruments
- Services and Software

Market, by Disease Type

- Hepatitis
- HIV

- CT/NG
- HAIs
- HPV
- TB
- Influenza
- Other Diseases

Market, by Technology

- Immunodiagnostics
- Clinical Microbiology
- PCR
- INAAT
- DNA Sequencing & NGS
- DNA Microarrays
- Other Technologies

Market, by End User

- Hospitals/Clinical Laboratories
- Reference Laboratories
- Physician Offices
- Academic/Research Institutes
- Other End Users

Regional Outlook

- North America
- U.K.
- Latin America
- Asia Pacific
- Middle East & Africa